Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

NCT05829460 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Low accrual

Conditions

Endometrial Hyperplasia

Interventions

DRUG: Semaglutide
DRUG: Placebo
DRUG: LNG-IUD (Progestin)
BEHAVIORAL: Telemedicine behavioral weight program

Sponsor

Washington University School of Medicine

Collaborators

[object Object]